Original article
Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase IIIb trial
Erradicación de Helicobacter pylori en México con un esquema basado en levofloxacina versus la triple terapia estándar: resultados de un estudio clínico de fase iiib, abierto, aleatorizado, de no inferioridad
L. Ladrón-de-Guevaraa, L. Bornstein-Quevedob, S. González-Huezoc, B. Castañeda-Romerod, F.G. Costae,
, M. di Silvio-Lópezf
Corresponding author
fcosta@asofarma.com
Corresponding author. Departamento de Estudios Clínicos, Laboratorio Asofarma S.A. y C. Crámer 4130/C1429AJZ. CABA, Argentina. Tel.: +54 11 4703-8661.
Corresponding author. Departamento de Estudios Clínicos, Laboratorio Asofarma S.A. y C. Crámer 4130/C1429AJZ. CABA, Argentina. Tel.: +54 11 4703-8661.
a Servicio de Gastroenterología, Hospital Ángeles Clínica Londres, Mexico City, Mexico
b Laboratorio de Inmunohistoquímica y Patología Molecular, InmunoQ, Mexico City, Mexico
c Servicio de Gastroenterología, Torre Mayo, Metepec, State of Mexico, Mexico
d Servicio de Gastroenterología, Hospital Ángeles Metropolitano, Mexico City, Mexico
e Laboratorio Asofarma S.A.I. y C. Argentina
f Servicio de Gastroenterología, Centro Médico ABC Observatorio, Mexico City, Mexico
Read
13695
Timeswas read the article
4164
Total PDF
9531
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 11 | 176 | 110 | 286 |
| 2025 10 | 355 | 148 | 503 |
| 2025 9 | 280 | 189 | 469 |
| 2025 8 | 309 | 107 | 416 |
| 2025 7 | 174 | 60 | 234 |
| 2025 6 | 213 | 40 | 253 |
| 2025 5 | 217 | 46 | 263 |
| 2025 4 | 247 | 38 | 285 |
| 2025 3 | 164 | 23 | 187 |
| 2025 2 | 105 | 19 | 124 |
| 2025 1 | 130 | 21 | 151 |
| 2024 12 | 105 | 24 | 129 |
| 2024 11 | 72 | 20 | 92 |
| 2024 10 | 76 | 26 | 102 |
| 2024 9 | 102 | 25 | 127 |
| 2024 8 | 119 | 32 | 151 |
| 2024 7 | 140 | 50 | 190 |
| 2024 6 | 125 | 56 | 181 |
| 2024 5 | 148 | 47 | 195 |
| 2024 4 | 141 | 39 | 180 |
| 2024 3 | 138 | 54 | 192 |
| 2024 2 | 124 | 70 | 194 |
| 2024 1 | 103 | 39 | 142 |
| 2023 12 | 118 | 53 | 171 |
| 2023 11 | 146 | 58 | 204 |
| 2023 10 | 117 | 70 | 187 |
| 2023 9 | 221 | 73 | 294 |
| 2023 8 | 207 | 21 | 228 |
| 2023 7 | 161 | 35 | 196 |
| 2023 6 | 145 | 35 | 180 |
| 2023 5 | 151 | 40 | 191 |
| 2023 4 | 91 | 19 | 110 |
| 2023 3 | 176 | 69 | 245 |
| 2023 2 | 113 | 32 | 145 |
| 2023 1 | 95 | 26 | 121 |
| 2022 12 | 144 | 52 | 196 |
| 2022 11 | 121 | 41 | 162 |
| 2022 10 | 123 | 50 | 173 |
| 2022 9 | 70 | 64 | 134 |
| 2022 8 | 71 | 46 | 117 |
| 2022 7 | 93 | 48 | 141 |
| 2022 6 | 79 | 48 | 127 |
| 2022 5 | 93 | 50 | 143 |
| 2022 4 | 96 | 63 | 159 |
| 2022 3 | 126 | 80 | 206 |
| 2022 2 | 99 | 63 | 162 |
| 2022 1 | 102 | 77 | 179 |
| 2021 12 | 72 | 68 | 140 |
| 2021 11 | 85 | 56 | 141 |
| 2021 10 | 108 | 112 | 220 |
| 2021 9 | 94 | 63 | 157 |
| 2021 8 | 85 | 75 | 160 |
| 2021 7 | 97 | 57 | 154 |
| 2021 6 | 87 | 85 | 172 |
| 2021 5 | 94 | 87 | 181 |
| 2021 4 | 171 | 178 | 349 |
| 2021 3 | 121 | 70 | 191 |
| 2021 2 | 70 | 37 | 107 |
| 2021 1 | 49 | 34 | 83 |
| 2020 12 | 35 | 19 | 54 |
| 2020 11 | 46 | 38 | 84 |
| 2020 10 | 38 | 31 | 69 |
| 2020 9 | 88 | 39 | 127 |
| 2020 8 | 44 | 28 | 72 |
| 2020 7 | 37 | 17 | 54 |
| 2020 6 | 31 | 19 | 50 |
| 2020 5 | 71 | 29 | 100 |
| 2020 4 | 71 | 21 | 92 |
| 2020 3 | 55 | 30 | 85 |
| 2020 2 | 177 | 24 | 201 |
| 2020 1 | 108 | 41 | 149 |
| 2019 12 | 91 | 37 | 128 |
| 2019 11 | 122 | 62 | 184 |
| 2019 10 | 70 | 43 | 113 |
| 2019 9 | 63 | 44 | 107 |
| 2019 8 | 59 | 29 | 88 |
| 2019 7 | 35 | 17 | 52 |
| 2019 6 | 37 | 19 | 56 |
| 2019 5 | 34 | 22 | 56 |
| 2019 4 | 38 | 23 | 61 |
| 2019 3 | 30 | 17 | 47 |
| 2019 2 | 25 | 15 | 40 |
| 2019 1 | 36 | 17 | 53 |
| 2018 12 | 30 | 14 | 44 |
| 2018 11 | 74 | 18 | 92 |
| 2018 10 | 127 | 28 | 155 |
| 2018 9 | 5 | 5 | 10 |
Show all
